22nd Century

Williamsville, United States Founded: 1998 • Age: 28 yrs Listed
Manufacturer of nicotine products

About 22nd Century

22nd Century is a publicly listed company based in Williamsville (United States) founded in 1998. Manufacturer of nicotine products. The company has 56 employees. 22nd Century has completed 2 acquisitions, including GVB Biopharma and RX Pharmatech. Its focus areas include Industrial Goods and Manufacturing and Manufacturing Services.

Company details

22nd Century manufacturer of nicotine products, focusing on industrial goods and manufacturing, and manufacturing services. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.

  • Headquarters Williamsville, United States
  • Employees 56
  • Stage Public
  • Sectors
    Industrial Goods & Manufacturing
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website xxiicentury.com
  • Social LinkedIn X Facebook
  • Legal Name 22Nd Century Group, Inc
Key Metrics
  • Annual Revenue
    $17.59 M (USD)
    -27.87
    as on Dec 31, 2025
  • Net Profit
    -$5.05 M (USD)
    66.67
    as on Dec 31, 2025
  • EBITDA
    -$10.26 M (USD)
    18.16
    as on Dec 31, 2025
  • Latest Funding Round
    $20M (USD), Post-IPO

    Mar 2026

  • Investors
  • Employee Count
    56
  • Investments & Acquisitions

Funding Insights of 22nd Century

  • Total Rounds 15
  • Last Round Post-IPO — $20M
  • First Round $5.4M

    (Jan 2011)

  • Investors Count 2

Latest 10 of 15 funding rounds of 22nd Century with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2026$20MPost-IPO––
–
Sep 2024$1.2MPost-IPO––
–
Apr 2024$4.2MPost-IPO––
–
Jul 2022$35MPost-IPO––
–
May 2022$58MPost-IPO––
–
Oct 2021$285,086Grant––
Jun 2021$40MPost-IPO––
–
Oct 2017$54MPost-IPO––
–
Sep 2014$10MPost-IPO––
–
Feb 2013$67,200Post-IPO––
–
Valuation history

2 investors in total: 2 institutional.

Investors in 22nd Century

22nd Century has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and Montrose Capital Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage investments in US tech and life sciences are targeted.
montrosecapital.comMiami, United States
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for 22nd Century

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of 22nd Century

19 people are tracked at 22nd Century (7 in leadership, 6 in board & advisors, 6 in team); the tracked headcount is 56.

NameRoleGroup
John Miller
President, Tobacco BusinessLeadership
R. Hugh Kinsman
CFOLeadership
James A. Mish
CEOLeadership
Daniel Otto
Chief Financial OfficerLeadership
Christine Hewitt Lanza
Vice President Of Government AffairsLeadership
John Franzino
Chief Administrative OfficerLeadership
Scott Marion
VP Of Manufacturing Operations And FinanceLeadership
Clifford B. Fleet
DirectorBoard & advisors
Lucille S. Salhany
DirectorBoard & advisors
Anthony Johnson
DirectorBoard & advisors
Nora B. Sullivan
ChairpersonBoard & advisors
Michael Koganov
DirectorBoard & advisors
Richard M. Sanders
DirectorBoard & advisors
McKenzee Heath
Human Resources ManagerTeam
Heather G.
Sr. Operations ManagerTeam
Darin Quesinberry
ManagerTeam
Ashley Loraine Crangle
Brand AmbassadorTeam
Michaela Kolander
Project ManagerTeam
Justin L.
Regulatory Compliance ManagerTeam
Premium access

Complete people profiles for 22nd Century

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of 22nd Century

22nd Century is a publicly listed company on the NASDAQ with ticker symbol XXII in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date31 Jan 2011
  • Listed onNASDAQ: XXII
  • Listed entity22nd Century Group, Inc
  • Exchange sectorHealth technology
  • ISINUS90137F7078
  • Share price$0.67 (-7.98% on the day) · 2026-10-13
  • Market capitalisation$475,948.00
  • EPS (diluted, trailing year)$-644.21
  • Volume (last session)79,207

Financials of 22nd Century

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$17.6M-$5.0M-$10.3M
2024$24.4M-$15.2M-$12.5M
2023$32.2M-$140.8M-$37.1M
2022$40.5M-$59.8M-$29.7M
2021$30.9M-$32.6M-$26.8M
Premium access

Detailed financial statements for 22nd Century

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by 22nd Century

22nd Century has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include GVB Biopharma and RX Pharmatech.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Cannabis-based products are cultivated and produced by RX Pharmatech.
Bradford, United Kingdom2016Jan 2023••••
Cannabis extracts and white label solutions are provided globally.
gvbbiopharma.comUnited States2016May 2022••••
Premium access

Complete acquisition details for 22nd Century

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of 22nd Century

6 dated milestones of 22nd Century across 28 years, from founding to its latest funding, stage changes and deals.

  1. Founded 22nd Century is founded.
  2. Funding First funding round of $5.4M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires GVB Biopharma.
  5. Acquisition Acquires RX Pharmatech.
  6. Funding Latest funding round, Post-IPO, of $20.0M.

Web traffic of 22nd Century

The website of 22nd Century (xxiicentury.com) receives about 7.8K visits a month.

  • Monthly visits
    7.8K

    ▲ 14.3% vs previous month

Similar websites

Websites whose visitors overlap most with 22nd Century. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
businesswire.com
100%
2.5M#30,232View details
handelsblatt.com
100%
17.9M#4,781View details

Top companies in Contract & Outsourced Manufacturing

3 companies that operate in the same segment as 22nd Century (Contract & Outsourced Manufacturing) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Designer and producer of intelligent products, automotive electronics manufacturing, and logistics services
1969San Jose, California, United StatesUSD 5.06 MUSD 27.91 B147,980
Equipment and parts for HVAC/R industry are supplied.
1956Miami, Florida, United StatesUSD 7.24 B7,290
Wood-fired grills are manufactured and supplied by Traeger.
1987Salt Lake City, Utah, United StatesUSD 559.52 M666
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about 22Nd Century

Premium access

Complete news archive for 22nd Century

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about 22nd Century

22nd Century was founded in 1998 and raised its 1st funding round 13 years after it was founded.

22nd Century is headquartered in Williamsville, United States. It is registered at Williamsville, New York, United States.

22nd Century has 56 employees.

Annual revenue of 22nd Century is $17.59M as on Dec 31, 2025.

22nd Century manufacturer of nicotine products, focusing on industrial goods and manufacturing, and manufacturing services. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.

Yes, 22nd Century is publicly traded on NASDAQ under the ticker symbol XXII.

22nd Century has made 2 acquisitions, including GVB Biopharma, and RX Pharmatech.

22nd Century has 2 investors. Key investors include European Union, and Montrose Capital Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available